WORCESTER, Mass.--(BUSINESS WIRE)--RXi Pharmaceuticals (NASDAQ: RXII), a biopharmaceutical company pursuing the development and potential commercialization of proprietary therapeutics based on RNA interference (RNAi) for the treatment of human diseases, initiated trading today on the NASDAQ Capital Market.
